Depression in the Elderly: How to treat

Consultant

Volumn 52, Issue 4, 2012, Pages 267-278

  Khouzam, Hani Raoul ^a,b,c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Antidepressant; Depression; Elderly; Psychopharmacological treatment; Psychotherapy

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; AMOXAPINE; ASCENDIN; CHOLESTEROL; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; DESVENLAFAXINE; DOXEPIN; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; FLUVOXAMINE MALEATE; IMIPRAMINE; ISOCARBOXAZID; MAPROTILINE; MIRTAZAPINE; NEFAZODONE; NORTRIPTYLINE; PAROXETINE; PHENELZINE; PROTRIPTYLINE; SELEGILINE; SERTRALINE; TRANYLCYPROMINE; TRAZODONE; TRIACYLGLYCEROL; TRIMIPRAMINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VENLAFAXINE; VILAZODONE;

ACUPUNCTURE; AGITATION; AKATHISIA; ALCOHOLISM; ANOREXIA; ANXIETY DISORDER; BLURRED VISION; BODY MOVEMENT; BRAIN DEPTH STIMULATION; CHOLESTEROL BLOOD LEVEL; CLINICAL EFFECTIVENESS; COGNITIVE THERAPY; CONFUSION; CONSTIPATION; CONSULTATION; DECREASED APPETITE; DEPRESSION; DIAPHORESIS; DIARRHEA; DIZZINESS; DROWSINESS; DRUG ERUPTION; DRUG INDUCED HEADACHE; DYSPNEA; EJACULATION; ELECTROCONVULSIVE THERAPY; ERECTILE DYSFUNCTION; FAMILY THERAPY; FATIGUE; FLUSHING; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEALTH CARE; HUMAN; HYPERTENSION; HYPOTENSION; IMPOTENCE; INCREASED APPETITE; INSOMNIA; IRRITABILITY; MINOR DEPRESSION; MORBIDITY; MORTALITY; MUSCLE TONE; MYALGIA; NAUSEA; NAUSEA AND VOMITING; NERVOUSNESS; NIGHTMARE; PATIENT REFERRAL; PATIENT SAFETY; PRACTICE GUIDELINE; PRIAPISM; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROTEINURIA; PSYCHOEDUCATION; PSYCHOPHARMACOTHERAPY; PSYCHOTHERAPY; RESTLESSNESS; REVIEW; SEDATION; SEIZURE; SEXUAL BEHAVIOR; SIDE EFFECT; SKIN SENSITIVITY; SOCIAL SUPPORT; SOCIAL WORK; SOMNOLENCE; SPIRITUAL CARE; STOMACH PAIN; SUBSTANCE ABUSE; SWEATING; TINNITUS; TRANSCRANIAL MAGNETIC STIMULATION; TREMOR; TRIACYLGLYCEROL BLOOD LEVEL; VAGUS NERVE STIMULATION; VOMITING; WATER RETENTION; WEAKNESS; WEIGHT GAIN; WEIGHT REDUCTION; XEROSTOMIA;

EID: 84860672820     PISSN: 00107069     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (70)

1. Khouzam HR. The diagnosis and treatment of depression in the geriatric population. Comprehensive Therapy. 2009;35(2):103-114.
2. Hollon SD. Cognitive and behavior therapy in the treatment and prevention of depression. Depress Anxiety. 2011;28(4):263-266.
3. Zisook S, Shear K. Grief and bereavement: what psychiatrists need to know. World Psychiatry. 2009;8(2):67-74.
4. Birrer RB, Vemuri SP. Depression in later life: a diagnostic and therapeutic challenge. Am Fam Physician. 2004;69:2375-2382. (Pubitemid 38668130)
5. Gallo JJ, Coyne JC. The challenge of depression in late life: bridging science and service in primary care. JAMA. 2000;284:1570-1572.
6. Katon WJ, Lin E, Russo J, Unutzer J. Increased medical costs of a population-based sample of depressed elderly patients. Arch Gen Psychiatry. 2003;60:897.
7. Devanand DP, Adorno E, Cheng J. Late onset dysthymic disorder and major depression differ from early onset dysthymic disorder and major depression in elderly outpatients. J Affect Disord. 2004;78:259-267. (Pubitemid 38167746)
8. van der Wurff FB, Stek ML, Hoogendijk WJ, Beekman AT. The efficacy and safety of ECT in depressed older adults: a literature review. Int J Geriatr Psychiatry. 2003;18:894-904. (Pubitemid 37294851)
9. Borin L, Menon K, Raskin A, Ruskin P. Predictors of depression in geriatric medically ill inpatients. Int J Psychiatry Med. 2001;31:1-8. (Pubitemid 32762762)
10. Burke WJ, Wengel SP. Late-life mood disorders. Clin Geriatr Med. 2003;19:777-779.
11. Khouzam HR, Battista MA, Emes R, Ahles S. Psychoses in late life: evaluation and management of disorders seen in primary care. Geriatrics. 2005;60(3):26-33. (Pubitemid 40387756)
12. Williams M, Angstman K, Johnson I, Katzelnick DJ. Implementation of a care management model for depression at two primary care clinics Ambul Care Manage. 2011;34(2):163-173.
13. Coupland C, Dhiman P, Barton G, et al. A study of the safety and harms of antidepressant drugs for older people: a cohort study using a large primary care database. Health Technol Assess. 2011;15(28): 1-202.
14. Kelsey JE. Treatment strategies in achieving remission in major depressive disorder. Acta Psychiatrica Scandinavica, Supplement. 2002;106 (415):18-23. (Pubitemid 36135481)
15. Fava M, Rush AJ, Trivedi MH, et al. Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study. Psychiatric Clin North America. 2003;26(2): 457-494. (Pubitemid 36583573)
16. National Center for Biotechnology Information. U.S. National Library of Medicine. PubMed Drug & Supplements Monograph Citalopram. Available at: http://www.nlm.nih.gov/medlineplus/druginfo/meds/a699001.html1. Accessed July 20, 2011.
17. Whooley MA, Simon GE. Managing depression in medical outpatients. N Engl J Med. 2000;343: 1942-1950. (Pubitemid 32064789)
18. Blier P, Ward HE, Tremblay P, Laberge L, Hébert C, Bergeron R. Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study. Am J Psychiatry. 2010;167(3):281-288.
19. Fava M. Augmentation and combination strategies in treatment-resistant depression. J Clin Psychiatry. 2001;62(18):4-11. (Pubitemid 33736199)
20. Mendelson WB. A review of the evidence for the efficacy and safety of trazodone in insomnia. J Clin Psychiatry. 2005;66(4):469-476. (Pubitemid 40593575)
21. Khouzam HR. The antidepressant nefazodone: a review of its pharmacology, clinical efficacy, adverse effects, dosage and administration. Psychosocial Nurs Mental Health Series. 2000;38;20-25.
22. Khan A, Cutler AJ, Kajdasz DK, et al. A randomized, double-blind, placebo-controlled, 8-week study of vilazodone, a serotonergic agent for the treatment of major depressive disorder. J Clin Psychiatry. 2011; 72(4):441-447.
23. Glassman AH, Roose SP, Bigger JT Jr. The safety of tricyclic antidepressants in cardiac patients: risk/benefit reconsidered. JAMA. 1993;269:2673-2675. (Pubitemid 23147706)
24. Amsterdam JD, Hornig-Rohan M. Treatment algorithms in treatment-resistant depression. Psychiatric Clinics of North America. 1996;19(2):371-386. (Pubitemid 26184108)
25. Feiger AD, Rickels K, Rynn MA, Zimbroff DL, Robinson DS. Selegiline transdermal system for the treatment of major depressive disorder: an 8-week, double-blind, placebo-controlled, flexible-dose titration trial. J Clin Psychiatry. 2006;67(9):1354-1361. (Pubitemid 44583382)
26. Wecker L, James S, Copeland N, Pacheco MA. Transdermal selegiline: targeted effects on monoamine oxidases in the brain. Biol Psychiatry. 2003; 54(10):1099-1104. (Pubitemid 37415045)
27. Wenzel RG, Tepper S, Korab WE, Freitag F. Serotonin syndrome risks when combining SSRI/SNRI drugs and triptans: is the FDA's alert warranted? Ann Pharmacother. 2008;42(11):1692-1696.
28. Coupland C, Dhiman P, Barton G, et al. A study of the safety and harms of antidepressant drugs for older people: a cohort study using a large primary care database. Health Technol Assess. 2011;15(28): 1-202.
29. Katon W, Unützer J, Wells K, Jones L. Collaborative depression care: history, evolution and ways to enhance dissemination and sustainability. Gen Hosp Psychiatry. 2010;32(5):456-464.
30. Seemüller F, Schennach-Wolff R, Obermeier M, et al. Does early improvement in major depression protect against treatment emergent suicidal ideation? Affect Disord. 2010;124(1-2):183-186
31. Joffe RT. Hormone treatment of depression. Dialogues Clin Neurosci. 2011;13(1):127-138.
32. Khouzam HR, Emes R. The use of buspirone in primary care. Psychosocial Nursing and Mental Health Services. 2002;40(7):34-41.
33. Shelton RC, Osuntokun O, Heinloth AN, Corya SA. Therapeutic options for treatment-resistant depression. CNS Drugs. 2010;24(2):131-161.
34. Gournellis R, Oulis P, Michalopoulou P, et al. Dimensional approach to delusions in psychotic depression in the elderly: factor structure and clinical correlates Int J Geriatr Psychiatry. 2009;24(4): 363-368.
35. Nelson J, Papakostas G. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry. 2009;166(9):980-991.
36. Gill T, Khouzam HR, Tan D. E-FALCONS: A mnemonic for monitoring the prescribing of atypical antipsychotics. Geriatrics. 2004;59(8):41-45. (Pubitemid 39071589)
37. Chahine LM, Acar D, Chemali Z. The elderly safety imperative and antipsychotic usage. Harv Rev Psychiatry. 2010;18(3):158-172
38. Gallo JJ, Bogner HR, Morales KH, et al. The effect of a primary care practice-based depression intervention on mortality in older adults: a randomized trial. Ann Intern Med. 2007;146:689-698.
39. Desai AK. Use of psychopharmacologic agents in the elderly. Clin Geriatr Med. 2003;19:697-719. (Pubitemid 37466820)
40. Yee AH, Wijdicks EF. A perfect storm in the emergency department. Neurocrit Care. 2010; 12(2):258-260.
41. Preboth M. Clinical review of recent findings on the awareness, diagnosis and treatment of depression. Am Fam Physician. 2000;15;61(10):3158, 3160, 3167-3168.
42. Unützer J, Schoenbaum M, Katon WJ, et al. Healthcare costs associated with depression in medically ill fee-for-service Medicare participants. J Am Geriatr Soc. 2009;57:506-510.
43. Tominaga K, Okazaki M, Higuchi H, et al. Symptom predictors of response to electroconvulsive therapy in older patients with treatment-resistant depression. Int J Gen Med. 2011;4:515-519.
44. Sienaert P. What we have learned about electroconvulsive therapy and its relevance for the practising psychiatrist. Can J Psychiatry. 2011;56 (1):5-12.
45. O'Connor DW, Gardner B, Presnell I, et al. The effectiveness of continuation-maintenance ECT in reducing depressed older patients' hospital re-admissions. J Affect Disord. 2010;120(1-3): 62-66.
46. Allan CL, Herrmann LL, Ebmeier KP. Transcranial magnetic stimulation in the management of mood disorders. Neuropsychobiology. 2011;64(3): 163-169.
47. George MS, Post RM. Daily left prefrontal repetitive transcranial magnetic stimulation for acute treatment of medication-resistant depression. Am J Psychiatry. 2011;168(4):356-364.
48. Hirschfeld RM. Deep brain stimulation for treatment-resistant depression. Am J Psychiatry. 2011;168(5):455-456.
49. Soulas T, Sultan S, Gurruchaga JM, Palfi S, Fénelon G. Depression and coping as predictors of change after deep brain stimulation in Parkinson's disease. World Neurosurg. 2011;75(3-4):525-32.
50. Ondicova K, Pecenák J, Mravec B. The role of the vagus nerve in depression. Neuro. Endocrinol Lett. 2010;31(5):602-608.
51. Shuchman M. Approving the vagus-nerve stimulator for depression. N Engl J Med. 2007;356: 1604-1607. (Pubitemid 46631669)
52. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR). 4th ed. Washington, DC: American Psychiatric Association; 2000.
53. Terman M. Evolving applications of light therapy. Sleep Med Rev. 2007;11(6):497-507. (Pubitemid 350087709)
54. Flory R, Ametepe J, Bowers B. A randomized, placebo-controlled trial of bright light and high-density negative air ions for treatment of seasonal affective disorder. Psychiatry Res. 2010;177(1-2):101-108.
55. Nahas R, Sheikh O. Complementary and alternative medicine for the treatment of major depressive disorder. Can Fam Physician. 2011;57(6):659-563.
56. S-Adenosyl-L-Methionine for Treatment of Depression, Osteoarthritis, and Liver Disease. Summary, Evidence Report/Technology Assessment: Number 64. AHRQ Publication No. 02-E033, August 2002. Agency for Healthcare Research and Quality, Rockville, MD.
57. Weck F, Hautzinger M, Heidenreich T, Stangier U. Psychoeducation for depression - features of interventions and therapeutic competencies. Psychother Psychosom Med Psychol. 2011;61(3-4):148-153.
58. Shimazu K, Shimodera S, Mino Y, et al. Family psychoeducation for major depression: randomised controlled trial. Br J Psychiatry. 2011;198(5):385-390.
59. Arkowitz H, Westra HA. Introduction to the special series on motivational interviewing and psychotherapy J Clin Psychol. 2009;65(11):1149-1155.
60. Funderburk JS, Sugarman DE, Labbe AK, et al. Behavioral health interventions being implemented in a VA primary care system. J Clin Psychol Med Settings. 2011;18(1):22-29.
61. Cuijpers P, Geraedts AS, van Oppen P, et al. Interpersonal psychotherapy for depression: a meta-analysis. Am J Psychiatry. 2011;168(6):581-592.
62. Chong MS, Chan MP, Kang J, et al. a new model of delirium care in the acute geriatric setting: geriatric monitoring unit. BMC Geriatr. 2011;13; 11(1):41.
63. Piet J, Hougaard E. The effect of mindfulness-based cognitive therapy for prevention of relapse in recurrent major depressive disorder: A systematic review and meta-analysis. Clin Psychol Rev. 2011; 31(6):1032-1040.
64. Khouzam HR. Chronic fatigue syndrome: an update on treatment in primary care. Consultant. 2011;51(3):145-150.
65. Andreescu C, Reynolds CF 3rd. Late-life depression: evidence-based treatment and promising new directions for research and clinical practice. Psychiatr Clin North Am. 2011;34(2):335-55, vii-iii.
66. Maratos A, Crawford MJ, Procter S. Music therapy for depression: it seems to work, but how? Br J Psychiatry. 2011;199:92-93.
67. Ayalon L, Shiovitz-Ezra S. The relationship between loneliness and passive death wishes in the second half of life. Int Psychogeriatr. 2011;22:1-9.
68. Nasser EH, Overholser JC. Recovery from major depression: the role of support from family, friends, and spiritual beliefs. Acta Psychiatr Scand. 2005;111:125-132. (Pubitemid 40293179)
69. Stanley MA, Bush AL, Camp ME, et al. Older adults' preferences for religion/spirituality in treatment for anxiety and depression. Aging Ment Health. 2011;15(3):334-343.
70. Hofmann SG, Grossman P, Hinton DE. Loving-kindness and compassion meditation: Potential for psychological interventions. Clin Psychol Rev. 2011;31(7):1126-1132.